Prevalence and Assessment of Factors Associated with COVID-19 Vaccine Hesitancy in an Ethnic Minority Oncology Patient Population.

COVID vaccine ethnic minorities vaccine hesitancy

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
14 Oct 2022
Historique:
received: 02 09 2022
revised: 23 09 2022
accepted: 08 10 2022
entrez: 27 10 2022
pubmed: 28 10 2022
medline: 28 10 2022
Statut: epublish

Résumé

Complicating the COVID-19 pandemic are the healthcare disparities experienced by ethnic minorities, especially those with comorbidities including cancer. The introduction of COVID-19 vaccines has been instrumental in blunting the morbidity and mortality from the pandemic; however, vaccine hesitancy, particularly among ethnic minorities, has been a major concern. Thus, we sought to evaluate the knowledge and perspectives of COVID-19 and vaccines among our ethnic minority cancer patient population. Following an IRB approved protocol, questionnaires were completed by patients in a predominantly ethnic minority population at a single institution between 1 February and 30 June 2021. Included were any adult cancer patients with either a solid or hematologic malignancy. Among the 84 patients that were offered the questionnaires, 52 patients responded, with a median age of 63.5 years. Overall, 36% were non-Hispanic Blacks and 30% were Hispanics; 65% were receiving active treatment for their cancer. Seventy-nine percent believed COVID-19 to be dangerous or harmful to them, 61% were concerned about the side effects, yet 65% considered COVID-19 vaccines as safe. Among the seven patients that refused the vaccine, (71%, This exploratory study demonstrates that most ethnic minority cancer patients are receptive to vaccines, with a majority being vaccinated. However, we also discovered various reasons why this group of patients may not want be vaccinated, including concerns about side effects and perception that COVID-19 is not harmful. These findings can help us further understand the complex nature of vaccine hesitancy in ethnic minority cancer patients, and aid in developing future vaccine awareness strategies as the COVID-19 pandemic continues to evolve.

Sections du résumé

BACKGROUND BACKGROUND
Complicating the COVID-19 pandemic are the healthcare disparities experienced by ethnic minorities, especially those with comorbidities including cancer. The introduction of COVID-19 vaccines has been instrumental in blunting the morbidity and mortality from the pandemic; however, vaccine hesitancy, particularly among ethnic minorities, has been a major concern. Thus, we sought to evaluate the knowledge and perspectives of COVID-19 and vaccines among our ethnic minority cancer patient population.
METHODS METHODS
Following an IRB approved protocol, questionnaires were completed by patients in a predominantly ethnic minority population at a single institution between 1 February and 30 June 2021. Included were any adult cancer patients with either a solid or hematologic malignancy.
RESULTS RESULTS
Among the 84 patients that were offered the questionnaires, 52 patients responded, with a median age of 63.5 years. Overall, 36% were non-Hispanic Blacks and 30% were Hispanics; 65% were receiving active treatment for their cancer. Seventy-nine percent believed COVID-19 to be dangerous or harmful to them, 61% were concerned about the side effects, yet 65% considered COVID-19 vaccines as safe. Among the seven patients that refused the vaccine, (71%,
CONCLUSIONS CONCLUSIONS
This exploratory study demonstrates that most ethnic minority cancer patients are receptive to vaccines, with a majority being vaccinated. However, we also discovered various reasons why this group of patients may not want be vaccinated, including concerns about side effects and perception that COVID-19 is not harmful. These findings can help us further understand the complex nature of vaccine hesitancy in ethnic minority cancer patients, and aid in developing future vaccine awareness strategies as the COVID-19 pandemic continues to evolve.

Identifiants

pubmed: 36298576
pii: vaccines10101711
doi: 10.3390/vaccines10101711
pmc: PMC9611923
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

JAMA Netw Open. 2021 Sep 1;4(9):e2127582
pubmed: 34591103
MMWR Morb Mortal Wkly Rep. 2020 Jul 10;69(27):864-869
pubmed: 32644981
Vaccines (Basel). 2021 Sep 06;9(9):
pubmed: 34579231
MMWR Morb Mortal Wkly Rep. 2021 Aug 20;70(33):1114-1119
pubmed: 34411075
JAMA Netw Open. 2021 Oct 1;4(10):e2128575
pubmed: 34643719
J Cancer Educ. 2023 Apr;38(2):562-570
pubmed: 35344162
JMIR Form Res. 2022 Sep 2;6(9):e39144
pubmed: 35969516
Healthcare (Basel). 2021 Mar 19;9(3):
pubmed: 33808758
JAMA Oncol. 2021 Aug 1;7(8):1242-1244
pubmed: 34110371
J Cancer Res Clin Oncol. 2022 Jun;148(6):1363-1374
pubmed: 35218401
N Engl J Med. 2020 Jun 25;382(26):2534-2543
pubmed: 32459916
J Cancer Res Clin Oncol. 2023 May;149(5):1985-1992
pubmed: 35731276
Front Public Health. 2022 Jul 22;10:923815
pubmed: 35937267
Ann Epidemiol. 2020 Jul;47:37-44
pubmed: 32419766
J Integr Med. 2022 Jan;20(1):34-44
pubmed: 34774463
Surg Obes Relat Dis. 2020 Aug;16(8):1096-1099
pubmed: 32522406
JNCI Cancer Spectr. 2021 Jun 29;5(3):Pkab049
pubmed: 34195543
Vaccines (Basel). 2021 Apr 21;9(5):
pubmed: 33919048
Eur J Cancer. 2020 Nov;139:43-50
pubmed: 32971510
JAMA. 2021 Aug 17;326(7):609-610
pubmed: 34402817
Future Oncol. 2022 Feb;18(4):457-469
pubmed: 34851155
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Asia Pac J Clin Oncol. 2023 Feb;19(1):234-242
pubmed: 35851752
JMIR Public Health Surveill. 2022 Jan 5;8(1):e29872
pubmed: 34709184
Vaccines (Basel). 2022 May 26;10(6):
pubmed: 35746458
JAMA Netw Open. 2021 May 3;4(5):e2111629
pubmed: 34042990
Proc Natl Acad Sci U S A. 2021 Feb 2;118(5):
pubmed: 33446511
Hum Vaccin Immunother. 2021 Dec 2;17(12):4761-4798
pubmed: 34847822
Vaccines (Basel). 2021 Aug 08;9(8):
pubmed: 34452004
Radiology. 2020 Dec;297(3):E303-E312
pubmed: 32673191
Health Aff (Millwood). 2020 Jul;39(7):1253-1262
pubmed: 32437224
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
N Engl J Med. 2021 Jul 8;385(2):97-100
pubmed: 33789007
Ann Epidemiol. 2021 Oct;62:66-68
pubmed: 34161794
J Hematol Oncol. 2020 Jun 10;13(1):75
pubmed: 32522278
Ann Am Thorac Soc. 2020 Oct;17(10):1336-1339
pubmed: 32643398
J Clin Med. 2020 Jul 30;9(8):
pubmed: 32751633
Ann Oncol. 2021 May;32(5):673-674
pubmed: 33529740
Vaccines (Basel). 2022 Jun 28;10(7):
pubmed: 35891203
Future Oncol. 2021 Nov;17(31):4071-4079
pubmed: 34337969
J Ambul Care Manage. 2021 Jan/Mar;44(1):71-75
pubmed: 33165121
Med. 2021 May 14;2(5):498-501
pubmed: 33851144
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
PLoS One. 2022 May 12;17(5):e0266397
pubmed: 35550627
Front Med (Lausanne). 2021 Nov 03;8:741204
pubmed: 34805207
MMWR Morb Mortal Wkly Rep. 2021 Apr 09;70(14):519-522
pubmed: 33830988
Spat Spatiotemporal Epidemiol. 2020 Aug;34:100355
pubmed: 32807400
JAMA. 2020 Jul 28;324(4):392-395
pubmed: 32556212
PLoS One. 2022 May 3;17(5):e0268020
pubmed: 35503797
J Racial Ethn Health Disparities. 2023 Feb;10(1):462-474
pubmed: 35182372
Ann Fam Med. 2022 Apr 01;(20 Suppl 1):
pubmed: 36857124
J Behav Med. 2023 Apr;46(1-2):366-376
pubmed: 35305205
Infect Drug Resist. 2021 Nov 23;14:4865-4876
pubmed: 34848979

Auteurs

Matthew Lee (M)

Department of Oncology, Montefiore Einstein Cancer Center (MECC), Bronx, NY 10461, USA.

Emily Miao (E)

Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Bruce Rapkin (B)

Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Balazs Halmos (B)

Department of Oncology, Montefiore Einstein Cancer Center (MECC), Bronx, NY 10461, USA.

Viswanathan Shankar (V)

Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Sanjay Goel (S)

Department of Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.

Classifications MeSH